These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18191815)

  • 1. Lobeline effects on tonic and methamphetamine-induced dopamine release.
    Wilhelm CJ; Johnson RA; Eshleman AJ; Janowsky A
    Biochem Pharmacol; 2008 Mar; 75(6):1411-5. PubMed ID: 18191815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
    Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.
    Wilhelm CJ; Johnson RA; Lysko PG; Eshleman AJ; Janowsky A
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1142-51. PubMed ID: 15102929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
    Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
    Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
    J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
    Ding D; Nickell JR; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2613-6. PubMed ID: 25991431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
    Eyerman DJ; Yamamoto BK
    J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
    Nickell JR; Siripurapu KB; Vartak A; Crooks PA; Dwoskin LP
    Adv Pharmacol; 2014; 69():71-106. PubMed ID: 24484975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
    Beckmann JS; Siripurapu KB; Nickell JR; Horton DB; Denehy ED; Vartak A; Crooks PA; Dwoskin LP; Bardo MT
    J Pharmacol Exp Ther; 2010 Dec; 335(3):841-51. PubMed ID: 20805303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.
    Freyberg Z; Sonders MS; Aguilar JI; Hiranita T; Karam CS; Flores J; Pizzo AB; Zhang Y; Farino ZJ; Chen A; Martin CA; Kopajtic TA; Fei H; Hu G; Lin YY; Mosharov EV; McCabe BD; Freyberg R; Wimalasena K; Hsin LW; Sames D; Krantz DE; Katz JL; Sulzer D; Javitch JA
    Nat Commun; 2016 Feb; 7():10652. PubMed ID: 26879809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in dopamine- and vesicular monoamine-transporter functions.
    Dluzen DE; McDermott JL
    Ann N Y Acad Sci; 2008 Oct; 1139():140-50. PubMed ID: 18991858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
    Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
    Brown JM; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methamphetamine self-administration acutely decreases monoaminergic transporter function.
    McFadden LM; Stout KA; Vieira-Brock PL; Allen SC; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
    Synapse; 2012 Mar; 66(3):240-5. PubMed ID: 22120988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
    Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
    AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lobeline inhibits the neurochemical and behavioral effects of amphetamine.
    Miller DK; Crooks PA; Teng L; Witkin JM; Munzar P; Goldberg SR; Acri JB; Dwoskin LP
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1023-34. PubMed ID: 11181937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
    Horton DB; Siripurapu KB; Norrholm SD; Culver JP; Hojahmat M; Beckmann JS; Harrod SB; Deaciuc AG; Bardo MT; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Mar; 336(3):940-51. PubMed ID: 21177475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.
    Nickell JR; Siripurapu KB; Horton DB; Zheng G; Crooks PA; Dwoskin LP
    Eur J Pharmacol; 2017 Jan; 795():143-149. PubMed ID: 27986625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A history of ethanol drinking increases locomotor stimulation and blunts enhancement of dendritic dopamine transmission by methamphetamine.
    Tschumi CW; Daszkowski AW; Sharpe AL; Trzeciak M; Beckstead MJ
    Addict Biol; 2020 Jul; 25(4):e12763. PubMed ID: 31062485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
    Joolakanti SR; Nickell JR; Janganati V; Zheng G; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2016 May; 26(10):2422-2427. PubMed ID: 27080180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.